Trial · NCT02874664
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in QTcF interval from baseline QTcF following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors. | 12 weeks | |
| Secondary | Change in RR interval from baseline RR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors. | 12 weeks | |
| Secondary | Change in PR interval from baseline PR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors. | 12 weeks | |
| Secondary | Change in QRS duration interval from baseline QRS duration following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors. | 12 weeks | |
| Secondary | Change in waveform composition interval from baseline waveform composition following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors. | 12 weeks | |
| Secondary | Relationship between plasma rovalpituzumab tesirine concentration and change in QTcF interval from baseline. | 12 weeks | |
| Secondary | Incidence of proarrhythmic adverse events stratified by change in QTcF from baseline of less than 10 ms or greater than 10 ms. | 12 weeks | |
| Secondary | Incidence of adverse events. | From first dose through 30 days post-last-dose | |
| Secondary | Objective response rate | Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months. | |
| Secondary | Duration of response | Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months. | |
| Secondary | Progression free survival | Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months. | |
| Secondary | Overall survival | Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months. | |
| Secondary | Clinical benefit ratio | Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months. | |
| Secondary | Maximum Plasma Concentration (Cmax) | Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose. | |
| Secondary | Area Under the Curve (AUC) | Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02874664/registered